Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis

Area of Science:

• Neuro-oncology
• Geriatric Medicine
• Clinical Pharmacology

Background:

• Elderly patients with primary central nervous system lymphoma (PCNSL) exhibit poor tolerance to combined radio-chemotherapy due to leuco-encephalopathy.
• Current understanding of treatment efficacy and toxicity for this demographic outside clinical studies is limited.

Purpose of the Study:

• To retrospectively analyze the efficacy and toxicity of different treatment modalities for elderly patients with PCNSL.
• To identify prognostic factors influencing survival in this patient population.

Main Methods:

• Retrospective analysis of 74 patients aged 60+ with PCNSL from five Dutch centers (1998-2007).
• Patients were categorized into radiotherapy alone, chemotherapy alone, or sequential chemo-radiotherapy groups.
• Karnofsky performance status (KPS) and treatment-related toxicities were assessed.

Main Results:

• Median overall survival was 20 months, significantly lower (4 months) for patients with KPS <70 compared to KPS ≥70 (25 months).
• Treatment modality was not an independent prognostic factor.
• Methotrexate (3 g/m²) resulted in two toxic deaths and ten discontinuations due to toxicity; delayed encephalopathy occurred in 10 patients.

Conclusions:

• Community hospitals frequently use whole-brain radiotherapy for elderly PCNSL patients, despite a majority tolerating chemotherapy well.
• Patient performance status is the most critical prognostic variable.
• Treatment decisions for elderly PCNSL patients necessitate individualized assessment of short- and long-term toxicities against potential clinical benefits.